Publication

Home/Publication

Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine

Poster EUROoCS H. Le et al. EUROoCS 2020 Download the [...]

By |2020-07-10T17:23:17+02:00July 8th, 2020|Publication|Comments Off on Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster [...]

By |2020-06-22T18:32:23+02:00June 22nd, 2020|BT-001, BT-001, Invir.IO, Publication|Comments Off on BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download [...]

By |2020-03-22T17:47:45+01:00November 8th, 2019|Publication, TG1050|Comments Off on Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane M. Harper, et al. Gynecologic Oncology, April 2019 - [...]

By |2020-07-22T14:05:49+02:00April 18th, 2019|Publication, TG4001, TG4001|Comments Off on The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up